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Abstract
Selective modulation of specific benzodiazepine receptor (BzR) gamma amino butyric acid-A
(GABAA) receptor ion channels has been identified as an important method for separating out the
variety of pharmacological effects elicited by BzR-related drugs. Importantly, it has been
demonstrated that both α2β(2/3)γ2 (α2BzR) and α3BzR (and/or α2/α3) BzR subtype selective
ligands exhibit anxiolytic effects with little or no sedation. Previously we have identified several
such ligands; however, three of our parent ligands exhibited significant metabolic liability in
rodents in the form of a labile ester group. Here eight analogs are reported which were designed to
circumvent this liability by utilizing a rational replacement of the ester moiety based on medicinal
chemistry precedents. In a metabolic stability study using human liver microsomes, four
compounds were found to undergo slower metabolic transformation, as compared to their
corresponding ester analogs. These compounds were also evaluated in in vitro binding as well as
efficacy assays. Additionally, bioisostere 11 was evaluated in a rodent model of anxiety. It
exhibited anxiolytic activity at doses of 10 and 100 mg/kg and was devoid of sedative properties.
1. Introduction
Gamma amino butyric acid-A (GABAA) receptors are the major inhibitory neurotransmitter
receptors of the central nervous system (CNS) and the site of action of a variety of
pharmacologically and clinically important drugs. Thus, benzodiazepines, barbiturates,
neuroactive steroids, anesthetics and convulsants exert their action by modulating the
function of these receptors.1 From the action of these drugs it is clear that GABAA receptors
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regulate numerous neurological functions including convulsions, anxiety, sedation, ataxia
and sleep activity, as well as memory and learning processes.2–5 GABAA receptors are
composed of 5 subunits that form a central chloride channel and can belong to different
subunit classes. A total of 19 subunits (6α, 3β, 3γ, 1δ, 1ε, 1π, 1θ, 3ρ) of the GABAA
receptor have been cloned and sequenced from the mammalian nervous system.6, 7 The
homology within each subunit class is about 60–80 %, while the homology between the
subunit classes is about 30–40 %.
The majority of GABAA receptors is composed of 1γ, 2α, and 2β subunits. The classical
benzodiazepines, such as diazepam or flunitrazepam, bind at the extracellular domain of the
α+γ2− interface of these receptors8 and exhibit a high affinity for receptors composed of
α1β(2/3)γ2, α2β(2/3)γ2, α3β(2/3)γ2 or α5β(2/3)γ2 subunits (diazepam sensitive receptors).
Different receptor subtypes reside within anatomically distinct regions of the brain and are
responsible for different physiological and pathological processes.9, 10 Data from knock in
mice indicate that the α1 containing receptors mediate the sedative, anticonvulsant, ataxic
effects, anterograde amnesia and abuse liability,11, 12 while the α2 and α313, 14 receptor
subtypes mediate anxiolytic activity.15–17 The α5 containing GABAA receptors have been
implicated in memory and learning processes,18,19 but seem neither to influence anxiolysis
nor motor effects,9, 19 although some reports of a decrease in locomoter effects due to α5
BzR subtype specific ligands have also been reported.20 It has been shown that a substantial
amount of agonist activity at the α1 BzR is required for effects on spatial learning and
memory impairments, while much weaker, but simultaneous activity at α1 and α5 together
is sufficient for eliciting sedation.21 Tolerance to some of the effects of benzodiazepines,
most notably the anticonvulsant and analgesic actions are mediated by the simultaneous
action of α1 and α5 BzR.22, 23
Agents selective for specific BzR subtypes should permit one to separate out the
pharmacological activities of these different isoforms and reduce the chances of tolerance
and abuse potential.12, 23–27 The GABAA/α1-selective positive allosteric modulators
alpidem and zolpidem are clinically prescribed as hypnotic agents suggesting that at least
much of the sedation associated with known anxiolytic drugs which act at the BzR binding
site is mediated through GABAA receptors containing the α1 subunit, as mentioned.
Consequently, novel benzodiazepine-like drugs that have pharmacological selectivity for α2
GABAA and/or α3 GABAA receptors and low receptor efficacy at α1GABAA and
α5GABAA receptors may be particularly useful as anxiolytics lacking sedative, ataxic, and
amnestic side effects as well as little or no abuse potential.11, 12
Recently, with the help of GABAA receptor point mutated mice, it was also demonstrated
that α2 and/or α3 receptor subtypes are largely responsible for the spinal antihyperalgesic
actions of classical benzodiazepines, while α1 receptors do not contribute.28 Interestingly, in
α1-GABAA receptor point-mutated mice, which are protected from the sedative effects of
diazepam, pronounced analgesia against formalin-induced pain has also been reported after
systemic treatment with diazepam.29 These results suggest that α1 sparing (non-sedative)
benzodiazepine-site agonists should exert a genuine analgesic effect after systemic
treatment.29
Through the iterative process of computational modeling and synthesis, benzodiazepine
derivatives, XHe-II-053 (1), HZ-166 (2), and JY-XHe-053 (3) have been synthesized in
Milwaukee (Figure 1). All three compounds 1-3 were exceptionally selective (hence non-
sedating) GABAA α2/α3 agonists in in vitro electrophysiological experiments (Figure
2).21, 30 In a rhesus monkey conflict procedure, over the dose range tested (0.1 to 10 mg/kg),
1 and 2 produced an anti-conflict effect without producing diazepam-like alterations in the
absence of response-contingent electric shock (non-suppressed responding). Both the
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compounds were anxiolytic, but lacked sedative, ataxic, muscle relaxant and amnestic side
effects.30 The 2′-F ligand 3 also produced a robust anti-conflict effect; however, it also
produced some reduction in response rates at the highest dose tested. This was, presumably,
due to its greater efficacy at GABAA α1 receptors as compared to α2 or α3 BzR ligands,
clearly illustrating the subtle differences that structures have on efficacy of ligands at
GABAA α1 BzR.
In another study in mouse models of neuropathic and inflammatory pain, α2/α3 ligand 2
exhibited a dose-dependent antihyperalgesic effect and was as efficacious as gabapentin.31
This antihyperalgesic activity was antagonized by flumazenil and hence mediated via the
benzodiazepine-binding site of GABAA receptors. At doses producing maximal
antihyperalgesia, ligand 2 was devoid of sedation and motor impairment, and showed no
loss of analgesic activity during a 9-day chronic treatment period (i.e. no tolerance
development) versus acute treatment.23
In preclinical studies 1 was shown to be safe and effective (anxiolytic but not sedating, not
ataxic, and had reduced abuse potential in rodents and was anxiolytic in non-human primate
models).30 Because of its encouraging results in pre-clinical testing, 1 had been taken into
Phase I studies in humans for anxiety disorders (Bristol-Myers Squibb, unpublished results
of Phase I trials). Ligand 1 was found to be safe in humans. It was found to be stable in
human blood, plasma, brain and kidney (Mithridion, unpublished results). However, in
human liver, ligand 1 was largely transformed into the inactive metabolite XHe-II-053-acid
(4) via hepatic enzymes, resulting in sub-optimal pharmacokinetics (unpublished results).
The related analog mining was an effort to circumvent the metabolic liability of these
compounds in human liver microsomes vs the control anxiolytic 1, in an effort to develop
nonsedating anxiolytics with longer half lives in humans.
A metabolic stability study of these compounds was undertaken at SRI International by Dr.
Ng and coworkers as a collaborative project funded by National Institute of Mental Health
(NIMH). In this study the test compounds were incubated with pooled human liver
microsomes and the aliquots were analyzed at various time points using LC-MS/MS.
Illustrated in Table 1 are the results from this study. Significant metabolic lability was
observed at both 1 and 10 μM for 1 (less than 14% remaining at 30 min) and 3 (less than
20% remaining at 15 min), while the key ligand 2 underwent minimal metabolism (80%
remaining at 60 min). The corresponding carboxylic acid controls of 1 and 2, i.e. acids 4 and
SR-II-54 (5), did not exhibit any metabolism during the test period. Additionally, all the
compounds when incubated with heat-inactivated human liver microsomes underwent no
significant change in the % remaining of any of the compounds, suggesting that the
compounds were stable under the control incubation conditions. These results indicated that
the main site of metabolism in human liver was due to the pendant ethyl ester moiety, which
was not unexpected but designed as a method of clearance (metabolic switching).
2. Design of novel ligands
Based on these findings it was decided to design novel analogs with bioisosteric replacement
of the labile ethyl ester moiety of the lead analogs (Figure 1). Amides are well known
bioisosteric replacements for substituted esters. Hence compounds 6-8 were synthesized
(Figure 2). The N,N-dimethylamide ligand 9 was included to determine the importance of a
H-bond donor at that position as compared to amide 7. Previously, in the case of GABAA
modulators in the benzodiazepine series of compounds, it has been demonstrated that
replacement of the ethyl ester at the 3-position by a 1,2,4-oxadiazole moiety resulted in
higher intrinsic efficacy at benzodiazepine receptors, as compared to the corresponding ethyl
esters.32 Substituted 1,2,4-oxadiazoles are also metabolically stable and slightly less
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lipophilic than the corresponding ester derivatives.33 Hence compounds 10-13 were
synthesized based on molecular modeling to limit the number of compounds.34, 35
3. Synthesis
Ligands 6-8 were prepared by heating 1-3 with methylamine at 50 °C in ethanol in a sealed
vessel. Ligand 9 was synthesized by heating acyl chloride of 5 (obtained by treatment of 5
with thionyl chloride at room temperature) with dimethyl amine at reflux in the presence of
triethylamine. Ligands 10 and 11 were prepared by treatment of 1 with sodium hydride and
N-hydroxy-propanimidamide or N-hydroxy-2-methyl-propanimidamide, respectively, in
anhydrous THF at reflux in the presence of 4 Å molecular sieves. Ligands 12 and 13 were
prepared from 2 and 3, respectively, by treatment with sodium hydride followed by N-
hydroxy-2-methyl-propanimidamide in anhydrous THF at reflux in the presence of
molecular sieves (4 Å).
4. Results and discussion
4.1 In vitro metabolic stability of ligands 6-12
BzR ligands 6-8, 11 and 12 were evaluated for metabolic stability (Table 2). Bioisosteric
replacement of the ester moiety with an amide improved the metabolic stability of amides
6-8 in human microsomes. Monomethyl amide 6 (YT-III-31) exhibited a decreased rate of
metabolism, as compared to the corresponding ethyl ester analog 1 in liver microsomes;
however, over the period of 60 minutes almost 95% of the compound was metabolized.
However the N-methyl amide analog 7 (HJ-I-40) of anxiolytic/analgesic 2 was not
metabolized during the 60 minutes of incubation and exhibited improved metabolic stability
as compared to the ethyl ester analog 2 (HZ-166). Amide 8 (HJ-I-37, approximately 92%
remaining at the end of 60 min) was significantly more stable than the corresponding ethyl
ester analog 3, which had underwent biotransformation almost quantitatively. Substituted
1,2,4-oxadiazole analogs 11 (EMJ-I-026) and 12 (ZJW-II-40) were significantly more stable
than 1 and 2 respectively, as expected, based on medicinal chemistry precedents.
Further assessment of these compounds in regard to agonist efficacy at BzR was carried out
by in vitro electrophysiological studies on recombinant GABAA receptor subtypes expressed
in Xenopus oocytes.
4.1.2. In vitro Electrophysiological Studies on 6-8 and 11-13 for Efficacy at Bz/
GABAergic Receptor Subtypes—The dose-response curves for the stimulation of
GABA-induced currents by BDZs 6-8 and 11-13 in oocytes, which expressed GABAA
receptors of the subtypes α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2, are illustrated in Figures
3–8. Amide 6 exhibited the most selective efficacy at α3β3γ2 receptor subtypes. At 100 nM
concentration it exhibited very weak agonistic effects at α1β3γ2, α2β3γ2 and α5β3γ2;
while acting as an antagonist at α1β3γ2 and α5β3γ2 at higher concentration, which is
extremely desirable. This indicates that 6 is a potential nonsedating anxiolytic. Amides 7 and
8 exhibited selective efficacy at α3β3γ2 BzR at higher concentration. Ligand 7, however
was relatively less potent than 8. Dose-response curves for 11 indicated a maximum
separation between efficacies at α1β3γ2 and those at the other subtypes at physiologically
relevant concentrations (100 nM). Oxadiazole 12 exhibited selective efficacy at α3β3γ2,
however it was far less potent than 6 and 11. Oxadiazole 13, at lower concentration,
selectively modulated α5β3γ2 and α3β3γ2 receptor subtypes. At higher concentration this
compound modulated α3β3γ2 receptors with higher efficacy than α5β3γ2 receptors. In
general, all of the ligands exhibited the desired selective efficacy at the α3β3γ2 Bz receptor
subtype. Bioisostere 11 (EMJ-I-026) was selected for in vivo assessment for three reasons –
it exhibited relatively more selective efficacy at α3β3γ2 receptor subtypes at
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physiologically relevant concentrations, it was metabolically stable as indicated in the liver
microsomal assays, and it is a novel 1,2,4-oxadiazole analog.
4.1.3. Behavioral studies
Anxiolytic effect of 11 (EMJ-I-026) in the mouse model - The Light/Dark Cycle Test
and Locomotor Activity Test: “Anxiolytic-like behavior” of subtype selective and
metabolically stable oxadiazole 11 (EMJ-I-026) was tested in rodents using the light/dark
cycle test (Figure 9). Increased time spent in the lighted area compared to vehicle indicates
anti-anxiety effects. Diazepam was used as a positive control. Diazepam was significantly
anxiolytic as compared to vehicle, as expected. Oxadiazole 11 exhibited significant
anxiolytic activity at 10 and 100 mg/kg. Amphetamine-induced locomotor activity was a
measure of the animal’s activity related to sedation. Although this is not a direct measure of
sedation, it gives some idea about the sedative nature of a compound. Diazepam was used as
a positive control. Diazepam significantly reduced locomotor activity over vehicle i.e. an
indicator of sedation, while α3 subtype selective oxadiazole 11 at doses of 10 and 100 mg/
kg significantly increased locomotor activity. From this data, it was clear that α3 ligand 11
did not decrease locomotor activity. In these mice, there appeared to be no effects from
either ataxia or sedation. This indicated in this paradigm that 11 (EMJ-I-026) was a potential
nonsedating anxiolytic.
5. Summary
In this report, eight bioisosteric analogs of XHe-II-053 were designed in order to circumvent
any potential metabolic liability in humans of the previously described ligand. In fact, the
2′N-analog nonsedating anxiolytic HZ-166 (2) was nearly 80-fold more stable than XHe-
II-053 (1) after one hour (see table 1). Interestingly the 2′-F analog JY-XHe-053 (3) was not
very stable. Importantly, the 5 bioisosteric ligands tested comprised of amides (6-9) and
oxadiazoles (10-13) were much more stable on human liver microsomes than 1 again
indicating these bioisosteres (6-13) are potential nonsedating anxiolytics as well as HZ-166
(2) useful for treatment of anxiety disorders in human populations. Gratifyingly, ligands 6,
7, and 11 were clearly α3 Bz/GABAergic receptor subtype selective ligands at
pharmacologically relevant doses (approximately 100 nM) and, presumably, provide agents
to study physiologically processes mediated by α3 subtypes including anxiety and in
addition were much more stable on human liver microsomes than 1. In this regard α3
subtype selective ligand oxadiazole 11 (EMJ-I-026) has been evaluated in the light dark
paradigm and clearly is a nonsedating anxiolytic, wherein this ligand was anxiolytic with no
sedative properties, in vivo, as compared to diazepam in this paradigm. This study indicated
that the ester function in these molecules can be replaced with a metabolically more stable
ester bioisostere and still retain anxiolytic activity. The in depth study of these ligands in
animal models and other receptor systems is underway and will be reported in due course.
7. Experimental
7.1. General methods for organic synthesis
Proton and carbon nuclear magnetic resonance spectra were obtained on a Bruker 300-MHz
spectrometer. Chemical shifts are reported as parts per million (δ) using an internal standard
of residual CHCl3 (7.26 ppm). The low resolution mass spectra (LRMS) were obtained on
an electron impact (EI, 70 eV) mass spectrometer, which were recorded on a Hewlett-
Packard 5985B gas chromatography-mass spectrometer, while high resolution mass spectra
(HRMS) were recorded on a VG Autospec (Manchester England) mass spectrometer. Infra-
red spectra were recorded on a Thermo Nicolet Nexus 870 FT-IR or a Perkin Elmer 1600
series FT-IR spectrometer. Elemental analyses were performed on a Carlo Erba model
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EA-1110 carbon, hydrogen, and nitrogen analyzer. All samples submitted for CHN analyses
were first dried under high vacuum for a minimum of six hours using a drying pistol with
isopropyl alcohol as the solvent with potassium hydroxide pellets in the drying bulb.
Melting points were taken on an Electrothermal model IA8100 digital melting point
apparatus and are uncorrected. Analytical thin layer chromatography plates employed were
Dynamic Adsorbents Inc UV active silica gel on plastic, while silica gel 60A, grade 60 for
flash and gravity chromatography, were purchased from E. M. Science. Tetrahydrofuran
(THF) was dried by distillation from sodium-benzophenone ketyl. Dichloromethane was
distilled from calcium hydride. Acetonitrile was used directly as received.
7.1.1. 8-Ethynyl-N-methyl-6-phenyl-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-
diazepine-3-carboxamide (6)36—Ester 1 (355 mg, 1 mmol) was treated with
methylamine (33% wt solution in ethanol, 10 mL). The suspension which resulted was
stirred in a sealed vessel at 45–50 °C for 24 h during which time it became a clear solution.
After removal of the ethanol and methylamine under reduced pressure, the residue was
purified by a wash column (silica gel, gradient elution CH2Cl2-0.5% MeOH in CH2Cl2) to
afford amide 6 as a white powder (238 mg, 0.7 mmol, 70%): mp 237–238°C; IR (KBr)
3284, 1651, 1607, 1567, 1525, 1409, 1303, 1256, 1208, 1010, 942, 826, 782, 765, 743, 698
cm−1. 1H NMR (CDCl3) δ 2.99-2.97(d, 3H, J = 5.04 Hz), 3.17(s, 1H), 4.09-4.05(d, 1H, J =
12.1 Hz), 6.29-6.26 (d, 1H, J = 10.7 Hz), 7.09-7.08 (t, 1H), 7.59-7.36 (m, 7H), 7.78-7.75
(dd, 1H, J = 1.8 Hz and 1.6 Hz), 7.85 (s, 1H); MS (EI) m/e(relative intensity) 340 (M+, 100).
HRMS(TOF) Calcd for C21H16N4ONa (M+Na)+ 363.1222, found: 363.1202. CHN
Analysis: Anal. Calcd. for C21H16N4O•0.95 H2O: C, 70.56; H, 5.05; N, 15.67. Found: C,
70.58; H, 4.82; N, 15.20.
7.1.2. 8-Ethynyl-N-methyl-6-(pyridine-2-yl)-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-
diazepine-3-carboxamide (7)—Target 7 was prepared in 80% yield from 230 using the
procedure as described above. 7: mp 215–216 °C; 1H NMR (CDCl3) δ 2.97–2.99 (d, 3H, J =
4.9 Hz), 3.16 (s, 1H), 4.12 (bs, 1H), 6.29 (bs, 1H), 7.14–7.15 (bs, 1H), 7.33–7.37 (t, 1H),
7.51–7.57 (m, 2H), 7.71–7.84 (m, 3H), 8.12–8.15 (d, 1H), 8.55–8.57 (d, 1H). C20H15N5O;
MS (EI) m/e (relative intensity) 341(M+, 100), 342 (22). HRMS(TOF) Calcd for
C20H16N5O(M+H)+ 342.1355, found: 342.1365.
7.1.3. 8-Ethynyl-N-methyl-6-(2-fluorophenyl)-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-
diazepine-3-carboxamide (8)—Amide 8 was prepared in 75% yield from 331 using the
procedure analogous to the one used for the synthesis of 6. Compound 8: mp 235–236
°C; 1H NMR (CDCl3) δ 2.96–2.98 (d, 3H, J = 4.57 Hz), 3.16 (s, 1H), 4.10 (bs, 1H), 6.29
(bs, 1H), 6.96–7.02 (t, 1H), 7.14 (bs, 1H), 7.21–7.26 (t, 1H), 7.39–7.46 (m, 2H), 7.52–7.55
(d, 1H), 7.65–7.73 (m, 2H), 7.86 (s, 1H). C21H15FN4O; MS (EI) m/e (relative intensity) 358
(M+, 100), 359 (23). HRMS(TOF) Calcd for C20H15FN4ONa (M+Na)+ 381.1128, found:
381.1140. CHN Analysis: Anal. Calcd. for C21H15FN4O•0.17 CH2Cl2: C, 68.21; H, 4.15; N,
15.03. Found: C, 68.29; H, 4.28; N, 14.71.
7.1.4. 8-Ethynyl-N, N-dimethyl-6-(pyridine-2-yl)-4H-benzo-[f]-imidazo-[1,5-a]-
[1,4]-diazepine-3-carboxamide (9)36—Acid 5 (328 mg, 1 mmol) was dissolved in
CH2Cl2 (5 mL). To the suspension which resulted was added SOCl2 (0.5 mL) and the
mixture was stirred at rt for 1 h during which time it became a clear solution. After
removing the solvent and SOCl2 under reduced pressure, the residue was redissolved in
CH2Cl2 (5 mL) and was treated with Et3N (0.2 mL) and Me2NH (0.2 mL). After stirring at
reflux for 8 h, the reaction was quenched with water (5 mL). The organic layer was washed
with brine (5 mL) and dried (Na2SO4). After removal of the solvent under reduced pressure,
the residue was purified by a wash column (silica gel, gradient elution CH2Cl2-0.5% MeOH
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in CH2Cl2) to afford amide 9 (178 mg, 0.5 mmol, 50%) as a light yellow powder: mp 193–
194°C. 1H NMR (CDCl3) δ 3.10(s, 3H), 3.16(s, 1H), 3.35(s, 1H), 4.17–4.21(d, 1H, J =
12.09 Hz), 5.89–5.93(d, 1H, J = 12 Hz), 7.35–7.39(m, 1H), 7.52–7.55(m, 2H), 7.73–7.86(m,
3H), 8.10-8.07(d, 1H, J = 7.8 Hz), 8.58–8.59(d, 1H, J = 4.8 Hz); 13C NMR (CDCl3) δ 35.9,
39.1, 45.2, 79.3, 81.8, 120.9, 122.7, 124, 124.7, 127, 132.6, 133.3, 135.2, 135.8, 136.2,
136.8, 136.9, 148.7, 156.7, 164.5, 167.4. HRMS (ESI) m/z calcd for C21H18N5O (M+H)+
356.1511, found: 356.1528.
7.1.5. 5-(8-Ethynyl-6-phenyl-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-diazepine-3-
ethyl-1,2,4-oxadiazole (10)23—Ethyl amido oxime (59.5 mg, 0.676 mmol) was added to
a stirred suspension of powdered 4 Å molecular sieves (75 mg) in anhydrous THF (15 mL)
under argon. After the mixture was allowed to stir at rt for 10 min, NaH (60 % dispersion in
mineral oil; 0.676 mmol) was added to the mixture. After the mixture had stirred for another
30 min, a solution of the forgoing ester 1 (120 mg, 0.338 mmol) in THF (20 mL) was added.
The mixture, which resulted, was heated at reflux for 8 h. The reaction mixture was then
cooled to rt, after which acetic acid (40.6 mg, 0.676 mmol) was added. After the solution
was stirred for 10 min, the mixture was filtered through celite. The filtrate was diluted with
CH2Cl2 (50 mL) and washed sequentially with water, brine, and then dried (K2CO3).
Evaporation of the solvent under reduced pressure afforded a pale yellow solid, which was
purified by flash column chromatography (silica gel, EtOAc/hexane, 2:3) to furnish 10 as a
white solid (52 mg, 40%): mp 221–222°C; IR (KBr)ν 3297, 3105, 1603, 1570, 1495, 1310,
938 cm−1. 1H NMR (CDCl3) δ 8.07 (s, 1H), 7.80 (dd, 1H, J1 = 8.4 Hz, J2 = 1.8 Hz), 7.64-7.6
(m, 2H), 7.53-7.37 (m, 5H), 6.12 (d, 1H, J = 12.9 Hz), 4.21 (d, 1H, J = 12.9 Hz), 3.20 (s,
1H), 2.88 and 2.83 (Abq, 2H, J = 7.6 Hz), 1.41 (t, 3H, J = 7.6 Hz); 13C NMR (300 MHz,
CDCl3) δ 171.8, 170.6, 168.8, 139.1, 136.6, 135.8, 135.4 (2C), 135.1, 130.7, 129.3 (2C),
128.3 (2C), 128.1, 124.7, 122.7, 121.6, 81.2, 80, 44.7, 19.7, 11.5. MS(EI) m/e (relative
intensity) 379 (M+, 100).
7.1.6. 5-(8-Ethynyl-6-phenyl-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-diazepine-3-
isopropyl-1,2,4-oxadiazole (11)36—Isopropyl amido oxime (95 mg, 0.931 mmol) was
added to a stirred suspension of powdered 4 Å molecular sieves (100 mg) in anhydrous THF
(30 mL) under argon. After the mixture was allowed to stir at rt for 10 min, NaH (60 %
dispersion in mineral oil; 0.931 mmol) was added to the mixture. After the mixture was
stirred for a further 30 min, a solution of the forgoing ester 1 (165 mg, 0.465 mmol) in THF
(30 mL) was added. The mixture which resulted was heated to reflux for 8 h. The reaction
mixture was then cooled to rt, after which acetic acid (56 mg, 0.931 mmol) was added. After
the solution was stirred for 10 min, the mixture was filtered through celite. The filtrate was
diluted with CH2Cl2 (75 mL) and washed with water, brine and dried (K2CO3). Evaporation
of the solvent under reduced pressure afforded a pale yellow solid, which was purified by
flash column chromatography (silica gel, EtOAc/hexane, 2:3) to furnish 11 as a white solid
(82 mg, 0.209 mmol, 45%): mp 190°C; IR (KBr)ν 3291,3057, 2972, 1613, 1574, 1494,
1466, 1303, 1264, 939, 832, 781, 734, 699, 666 cm−1. 1H NMR (CDCl3) δ8.07(s, 1H),
7.81-7.79(dd, 1H), 7.64-7.61(m, 2H), 7.53-7.37(m, 5H), 6.14(d, 1H, J = 13.1 Hz), 4.19(d,
1H, J = 12.8 Hz), 3.20(s, 1H), 3.24-3.15(m, 1H), 1.44-1.41(d, 6H, J = 6.93 Hz); MS(EI) m/e
(relative intensity) 393(M+, 100). HRMS (TOF) Calcd for C24H19N5ONa(M+Na)+
416.1487, found: 416.1501. CHN Analysis: Anal. Calcd. for C24H19N5O•0.37 CH2Cl2: C,
68.89; H, 4.68; N, 16.48. Found: C, 68.94; H, 4.59; N, 16.32. (CHN sample was transferred
to a vial for drying with CH2Cl2 which may explain the contaminant.)
7.1.7. 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-
diazepine-3-yl)-3-isopropyl-1,2,4-oxadiazole (12)—Oxadiazole 12 was prepared in
40% yield from 2 using the same procedure employed for the synthesis of 11. 12: mp 200
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°C; 1H NMR (CDCl3) δ 1.42–1.44 (d, 6H, J = 6.93 Hz), 3.13–3.27 (m, 2H), 4.27–4.31 (d,
1H, J = 10.8 Hz), 6.14–6.18 (d, 1H, J = 10.8 Hz), 7.36–7.40 (m, 1H), 7.59–7.62 (m, 2H),
7.77–7.86 (m, 2H), 8.04–8.09 (m, 2H), 8.58–8.60 (m, 1H); 13C NMR (300 MHz, CDCl3) δ
20.5, 26.7, 44.8, 79.5, 81.5, 121.3, 122.7, 123.9, 124.8, 127, 135.2, 135.3, 135.7, 136, 136.2,
136.8, 148.7, 156.3, 167.8, 170.6, 175.2, 190.2; HRMS (ESI) Calcd for C23H19N6O (M+H)+
395.1620, found: 395.1635.
7.1.8. 5-(8-Ethynyl-6-(2-fluorophenyl)-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-
diazepine-3-yl)-3-isopropyl-1,2,4-oxadiazole (13)—Oxadiazole 13 was prepared in
45% yield from 3 using the procedure for the synthesis of 11. 13: mp 160–165°C; IR (neat)
ν3194, 2961,2924, 2854, 1631, 1610, 1495, 1450, 1414, 1394, 1367, 1342, 1312, 1259,
1221, 1071, 1011, 940, 903, 862, 793, 767, 754, 697, 671cm−1; 1H NMR (CDCl3) δ8.09(s,
1H), 7.80(dd, 1H, J = 1.78, 1.78 Hz), 7.69(m, 3H), 7.51(m, 2H), 7.07(m, 1H), 6.26(brs, 1H),
4.40(brs, 1H), 3.24 (m, 2H), 1.43(d, 6H, J = 6.93 Hz); MS (EI) m/e (relative intensity)
411(43), 383(M+, 98), 325(100), 299(74), 178(74), 57(57); HRMS(ESI) Calcd for
C24H18FN5O (M+H)+ 412.1644, found: 412.1628.
7.2. Electrophysiological experiments
Xenopus oocytes were injected with rat cDNA’s of GABAA receptor β3 and γ2 subunits as
well as α1, α2, α3, or α5 subunits21 36 hours after injection, the enveloping follicle cell
layers of the oocytes were removed and oocytes were placed on a nylon-grid in a bath of
Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 7.4), 1
mM MgCl2, 1 mM KCl and 1 mM CaCl2). For current measurements the oocytes were
impaled with two microelectrodes (2–3 mΩ), which were filled with 2 mM KCl. The oocytes
were constantly washed by a flow of 6 ml/min XR, which could be switched to XR
containing GABA and/or drugs. Drugs were diluted into XR from DMSO-solutions
resulting in a final concentration of 0.1 % DMSO perfusing the oocytes. Drugs were
preapplied for 30 sec before the addition of GABA, which was coapplied with the drugs
until a peak response was observed. Between two applications, oocytes were washed in XR
for up to 15 min to ensure full recovery from desensitization. All recordings were performed
at room temperature at a holding potential of −60 mV using a Warner OC-725C two-
electrode voltage clamp. Data were digitised, recorded and measured using a Digidata
1322A data acquisition system. Results of concentration response experiments were fitted
using GraphPad Prism 3.00 (GraphPad Software, San Diego, CA).
The equation used for fitting concentration response curves was Y=Bottom + (Top
−Bottom)/(1+10((LogEC50-X)*HillSlope)); X represents the logarithm of concentration, Y
represents the response; Y starts at Bottom and goes to Top with a sigmoid shape. This is
identical to the “four parameter logistic equation”.
7.3. Metabolic Stability for GABAA receptor ligands using human liver microsomes (SRI
study No. 400-10)
The test articles were incubated at two concentrations (1 and 10 μM) in 96-well plate format
with active or heat-inactivated human liver microsomes and cofactors. Aliquots were
removed at 0, 15, 30 and 60 minutes and mixed with acetonitrile containing internal
standard for analysis. Samples were extracted and assayed using a liquid chromatography/
tandem mass spectrometry (LC-MS/MS) analytical method. The test articles were prepared
as stock solutions in DMSO and stored in aliquots at −20 °C. On the day of the experiment,
the test articles were diluted in the 100 mM phosphate buffer (pH 7.4) to achieve appropriate
final concentrations.
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Pooled human liver microsomes (Lot # 38289, pool of 150 different male and female donor
livers) were obtained from BD Biosciences Corporation (Woburn, MA). Microsomes were
stored at ~ −135°C until use.
The test articles (1 and 10 μM) were incubated with human liver microsomes (0.5 mg
protein/ml) and appropriate cofactors (2.5 mM NADPH and 3.3 mM magnesium chloride)
in 100 mM phosphate buffer, pH 7.4 (0.1% final DMSO), in a 37°C water bath. Incubations
with all compounds were initiated with the addition of microsomes. At selected time points
(0, 15, 30 and 60 min), a single 100 μl aliquot was removed from each sample and mixed
with 200 μl of chilled acetonitrile containing internal standard. Following brief vortexing
and centrifugation, the samples were further diluted into a 96-well plate for subsequent LC-
MS/MS analysis. All samples were assayed in duplicate.
Experimental controls consisted of: a) incubation of all components except test article for 0
and 60 min, b) incubation of midazolam (positive control) at 10 μM for 0, 15, 30 and 60
min, and c) incubation of 1 and 10 μM test article and 10 μM midazolam with heat-
inactivated microsomes (0.5 mg protein/ml) for 0 and 60 min. All controls were assayed in
duplicate.
Samples were analyzed by LC-MS/MS in multiple reaction monitoring mode using positive-
ion electrospray ionization. The details of the LC-MS/MS method can be provided upon
request.
Data from the metabolic stability assays were transferred to and processed in a Microsoft
Excel spreadsheet. To determine metabolic stability, the percent remaining at each time
point was calculated by dividing the peak area ratio of test article/internal standard at each
time point by the peak area ratio at 0 min multiplied by 100.
7.4. The Light/Dark Cycle Test and Locomotor Activity Test on oxadiazole 11
Rats used for behavior were housed in a reverse light/dark cycle (lights on from 1900 to
0700 h) for at least 10 days before the start of behavioral experiments. Rats were
administered the diazepam (3 mg/kg, i.p.), test compound (10 mg/kg, i.p.), or SAL (2 ml/kg)
20 min before being placed in an open-field arena (Coulbourn Instruments, Allentown, PA)
in which spontaneous locomotor activity in the x–y plane was determined for 30 min by
beam breaks and recorded with TruScan software (Coulbourn Instruments). Rats were then
injected with D-amphetamine sulfate (0.5 mg/kg, i.p.) and locomotor activity recorded for
an additional 90 min.
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Structures of imidazobenzodiazepine-related ligands 1-5
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Pharmacokinetically-based bioisosteric analogs of the lead compounds 1-3 to increase
stability.
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Concentration–effect curves for 6 (YT-III-31) on α1β3γ2 (■), α2β3γ2 (▲), α3β3γ2 (◆),
and α5β3γ2 (▼) GABAA receptors, using an EC3 GABA concentration. Data points
represent the mean ± SEM from four oocytes (for each receptor subtype) from 2 batches.
Stimulation of GABA EC3 by compound 6 at 100 nM or 1 μM concentration was 132±11 or
192±30, 211±23 or 287±31, 412±41 or 831±106, and 257±28 or 307±36, for α1β3γ2,
α2β3γ2, α3β3γ2, and α5β3γ2 receptors, respectively.
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Concentration–effect curves for 7 (HJ-I-40) on α1β3γ2 (■), α2β3γ2 (▲), α3β3γ2 (▼),
andα5β3γ2 (◆) GABAA receptors, using an EC3 GABA concentration. Data points
represent the mean±SEM from at least three oocytes (for each receptor subtype) from ≥2
batches. Stimulation of GABA EC3 by compound 7 at 100 nM or 1 μM concentration was
117±3 or 171±12, 140±15 or 226±35, 163±5 or 376±27, and 122±5 or 182±9, for α1β3γ2,
α2β3γ2, α3β3γ2, and α5β3γ2 receptors, respectively.
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Concentration–effect curves for 8 (HJ-I-37) on α1β3γ2 (■), α2β3γ2 (▲), α3β3γ2 (◆),
and α5β3γ2 (▼) GABAA receptors, using an EC3 GABA concentration. Data points
represent the mean±SEM from at least three oocytes (for each receptor subtype) from 2
batches. Stimulation of GABA EC3 by compound 8 at 100 nM or 1 μM concentration was
152±6 or 201±15, 241±12 or 287±16, 349±60 or 485±37, and 326±9 or 361±4, for α1β3γ2,
α2β3γ2, α3β3γ2, and α5β3γ2 receptors, respectively.
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Concentration–effect curves for 11 (EMJ-I-026) on α1β3γ2 (■), α2β3γ2 (▲), α3β3γ2
(◆), and α5β3γ2 (▼) GABAA receptors, using an EC3 GABA concentration. Data points
represent the mean ± SEM from at least three oocytes (for each receptor subtype) from 2
batches. Stimulation of GABA EC3 by compound 11 at 100 nM or 1 μM concentration was
107±4 or 150±10, 160±3 or 281±13, 195±5 or 381±45, and 175±66 or 291±13, for α1β3γ2,
α2β3γ2, α3β3γ2, and α5β3γ2 receptors, respectively.
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Concentration–effect curves for 12 (ZJW-II-40) on α1β3γ2 (■), α2β3γ2 (▲), α3β3γ2
(▼), and α5β3γ2 (◆) GABAA receptors, using an EC3 GABA concentration. Data points
represent the mean ± SEM from four oocytes (for each receptor subtype) from ≥2 batches.
Stimulation of GABA EC3 by compound 12 at 100 nM or 1 μM concentration was 117±2 or
178±19, 139±6 or 236±37, 143±5 or 375±52, and 130±1 or 252±11, for α1β3γ2, α2β3γ2,
α3β3γ2, and α5β3γ2 receptors, respectively.
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Concentration–effect curves for 13 (YT-III-40) on α1β3γ2 (■), α2β3γ2 (▲), α3β3γ2 (◆),
and α5β3γ2 (▼) GABAA receptors, using an EC3 GABA concentration. Data points
represent the mean ± SEM from four oocytes (for each receptor subtype) from ≥2 batches.
Stimulation of GABA EC3 by compound 13 at 100 nM or 1 μM concentration was 140±8 or
234±37, 154±2 or 225±9, 226±53 or 460±53, and 239±23 or 331±21, for α1β3γ2,
α2β3γ2,, α3β3γ2, and α5β3γ2 receptors, respectively.
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The light/dark cycle test and locomotor activity test on oxadiazole agonist 11 (EMJ-I-026)
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